Insider trade

Chair sold ~$1.73M of DXCM shares in the open market

Traded Aug 20, 2026 · Filed Aug 24, 2026

DexcomDXCM

~$1.73M
Reported value · 19K sh @ $89.706: 310K
Holds after · shares reported: -4.4%
stock since the trade · S&P 500 +0.2%, $90.22 → $86.23 on Oct 1

Why it stands out

Dexcom's Executive Chair sold $1.73M of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 20, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 24, 2026

Chair$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,732,043

Shares × reported transaction price

Timing vs results

21 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $90.22 on Aug 20, 2026, within 2% of its 52-week high, after a 24% rise over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $91.48 (Aug 13, 2026), 97% of the way up, from 251 adjusted closes. 30 trading days earlier: $73.02 on Jul 9, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+1.1%	-0.5%	+1.6%
30 days	-1.9%	+0.2%	-2.1%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-26-000151
Filed / recorded: Aug 24, 2026, 8:01 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Kevin R Sayer
Relationship: Director, Officer
Officer title: Executive Chair
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 20, 2026
Transaction code: S
Shares / units: 19,308
Price per share: $89.706
Acquired / disposed: Disposed (D)
Shares owned after: 309,662
Ownership form: Direct
Amendment: No

Footnotes from the filing

On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Around the same time

Director sold ~$130K of Dexcom

Scheduled in advance3w ago

Director sold ~$550K of Dexcom

Scheduled in advance3w ago

Officer sold ~$143K of Dexcom

Scheduled in advance3w ago

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Footnotes from the filing

Around the same time

Most active this month